- Home
- S vs CRSP Comparison
S vs CRSP Comparison
Compare S & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- S
- CRSP
- Stock Information
- Founded
- S 2013
- CRSP 2013
- Country
- S United States
- CRSP Switzerland
- Employees
- S N/A
- CRSP N/A
- Industry
- S EDP Services
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- S Technology
- CRSP Health Care
- Exchange
- S Nasdaq
- CRSP Nasdaq
- Market Cap
- S 5.5B
- CRSP 4.9B
- IPO Year
- S 2021
- CRSP 2016
- Fundamental
- Price
- S $18.74
- CRSP $51.71
- Analyst Decision
- S Buy
- CRSP Buy
- Analyst Count
- S 30
- CRSP 16
- Target Price
- S $24.62
- CRSP $72.27
- AVG Volume (30 Days)
- S 5.9M
- CRSP 2.6M
- Earning Date
- S 08-28-2025
- CRSP 08-04-2025
- Dividend Yield
- S N/A
- CRSP N/A
- EPS Growth
- S N/A
- CRSP N/A
- EPS
- S N/A
- CRSP N/A
- Revenue
- S $864,135,000.00
- CRSP $38,050,000.00
- Revenue This Year
- S $24.05
- CRSP $11.17
- Revenue Next Year
- S $20.90
- CRSP $296.09
- P/E Ratio
- S N/A
- CRSP N/A
- Revenue Growth
- S 28.19
- CRSP N/A
- 52 Week Low
- S $15.36
- CRSP $30.04
- 52 Week High
- S $29.29
- CRSP $71.13
- Technical
- Relative Strength Index (RSI)
- S 61.95
- CRSP 42.60
- Support Level
- S $16.36
- CRSP $51.80
- Resistance Level
- S $17.09
- CRSP $55.30
- Average True Range (ATR)
- S 0.49
- CRSP 2.15
- MACD
- S 0.21
- CRSP -0.52
- Stochastic Oscillator
- S 86.67
- CRSP 10.99
About S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.